… ), the effect of treatment according to baseline DBP and the effect of treatment … heart
failure aetiology. As reported in another recent study, 8 we also analysed outcomes in patients …

… effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure
… We calculated HRs (95% CIs) for the effect of dapagliflozin 10 mg, compared with placebo…

… cardiovascular outcome trial to evaluate patients with type 2 diabetes mellitus stratified by
EF, we found that dapagliflozin reduced HHF in patients with … study shows that dapagliflozin …

… in patients with heart failure and reduced ejection fraction. In this analysis, we examine
the effects of dapagliflozin on a … , using the Kansas City Cardiomyopathy Questionnaire (KCCQ). …

… regarding the effects of SGLT2 inhibitors in patients with established heart … trial, we randomly
assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and …

… The aim of the study was to enroll patients with heart failure and reduced ejection fraction.
Individuals with type 2 diabetes were to continue to receive their glucose-lowering treatments, …

… In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …

… Consistent with previous data from comparably sized trials, dapagliflozin treatment had no
significant effect on natriuretic peptides 10 . Although natriuretic peptide levels are predictive …

… and reduced ejection fraction, use of dapagliflozin over 12 weeks did not affect … effects of
dapagliflozin in heart failure with reduced ejection fraction may potentially extend to patients …

… patients with heart failure and a left ventricular ejection fraction of more than 40% to receive
dapagliflozin (… The primary outcome was a composite of worsening heart failure (which was …